Atreca: Sequencing B cells

Atreca sequences B cells for antibodies; partnered with Gates for vaccines

Atreca Inc. is using high throughput B cell sequencing to identify and develop therapeutic antibodies, The company's technology is able to identify thousands of individual patient antibodies faster than techniques that require the use of cell culture.

Its first focus is vaccines, where it is working with the Bill & Melinda Gates Foundation.

Atreca is built on technology developed in the lab of co-founder William Robinson, associate professor of medicine

Read the full 685 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE